Vaxxas

📆 The countdown is on! Microneedles 2025 is coming to Brisbane next month, and the preliminary program is now LIVE!   In Brisbane and the southern hemisphere for the first time from 11 – 14 May 2025, this year’s program is centred around the theme "Pathways to Products" and reflects the significant advances in the technology over the past decade, and its transformative potential for transdermal delivery, diagnostics, and of course vaccine delivery.   #Vaxxas is excited to be a presenting partner for the event with @The University of Queensland, and we’re looking forward to welcoming to Brisbane a stellar line-up of experts in microneedle technology and its application in the broader healthcare landscape.   Booked your spot yet? Take a look through the program and register here: Microneedles 2025 | Brisbane, Australia   #Microneedles2025 #MedicalInnovation

MARCH! Great to have the Vaxxas team out connecting with many across the biotech industry and beyond this month, highlighting the great progress we’re making advancing our needle-free vaccination technology, the high-density microarray patch (HD-MAP). With the potential to remove cold-chain storage and distribution, lower the dose of vaccine required to protect against a wide range of diseases, and support lower-skilled or self-administration, the HD-MAP aims to transform the way vaccines are delivered globally.    Here are just a few highlights: 🚀 Team Vaxxas was among 300 guests at Brisbane City Hall to celebrate International Women’s Day The University of Queensland’s Women in Engineering breakfast including an engaging panel discussion moderated by #Vaxxas SVP Pipeline Development Deborah Pascoe, PhD.   👨🏻🔬👩🏻🔬 Vaxxas Scientists Jackie Creagh, Dr. Gowri Irgam, Sumedha (Sky) Seth, Kreshan Prem Kumar joined others for the UQ Biotechnology Society Industry night connecting UQ biotech students with Brisbane’s leading biotechnology companies, and helping to build valuable connections and opportunities to explore future career pathways. 💡 Vaxxas Chief Technology Officer Dr Angus Forster joined life science leaders from Australia and across the ditch at the 2025 BIOTech New Zealand Life Sciences Summit in Wellington sharing his insights on the opportunities and challenges that come with addressing a global unmet need as an Australian company.  #TeamVaxxas #LeadTheWay #MakeADifference Ellie O'Connell Rebecca Pawliw Sandra Depelsenaire Naomi Barker Justyna Lewko Sarah Atkinson Nhi Tran Bree Spohr

Rounding out our recent scientific advisor appointments, we’re excited to welcome Professor Paul Young to Vaxxas. A globally recognised virologist, Prof. Young has spent over 40 years researching virus-induced diseases, pioneering new diagnostics, and advancing vaccine and therapeutic strategies.   At The University of Queensland, Prof Young co-led the Australian consortium that developed an innovative COVID-19 vaccine in early 2020. His deep expertise in vaccine research and development will be invaluable as Vaxxas progresses its HD-MAP technology towards commercialisation.   "Vaxxas has made extraordinary progress in bringing the high-density microarray patch from concept through pre-clinical and extensive engineering development and now to clinical trials. The findings are extremely encouraging, and the company is poised to revolutionise vaccine delivery in the years ahead."   We’re honoured to have Prof. Young on board as we continue shaping the future of vaccine technology.   📆 Prof Young is also a Co-Chair and presenter at the upcoming International Conference on Microneedles being held in Brisbane from 11 – 14 May. Register now to be part of the global industry event @ https://lnkd.in/gya5dixG   #Vaxxas #MedicalInnovation #Vaccines #PublicHealth #GlobalHealth Microneedles 2025 | Brisbane, Australia

🚀 We’re excited to be adding another patent to our growing global IP portfolio.  Vaxxas has secured a new patent from the United States patent office covering our proprietary printhead system technology.  The printhead system is a critical component of our aseptic manufacturing process dispensing small doses of vaccine onto the tiny microprojections moulded into our high-density microarray patch (HD-MAP). When applied to the skin, the HD-MAP delivers the vaccine to the abundant immune cells below the skin surface. This latest patent adds to the more than 40+ issued patents supporting Vaxxas’ exclusive claim to manufacture and sell its proprietary vaccination technology, in the United States, Europe, Asia and Australia. Vaxxas is scaling up to manufacture and distribute vaccine patches for late-stage clinical trials and first commercial use from its global headquarters and state of the art biomedical facility in Brisbane. Read more here: https://lnkd.in/gBMKrCqC #Vaxxas #medicalinnovation #globalhealth #biotech 

🔬 Catch Vaxxas at #LifeSciencesSummit2025!   We're delighted to have Chief Technology Officer Dr Angus Forster representing Vaxxas at the 2025 BIOTech New Zealand Life Sciences Summit this week (18-19 March) in Wellington, NZ.   The way we administer vaccines hasn’t evolved from the traditional needle and syringe method for almost 200 years. This is an opportunity to hear how a breakthrough Australian technology could offer a needle-free delivery alternative and transform the way vaccines are administered in future.   In a keynote address, Dr Forster will cover: 💡 The unmet need for new vaccination technologies to help global governments make vaccination more accessible and convenient to more people 💡 The evolution of Vaxxas and its needle-free vaccine patch technology, the high-density microarray patch (HD-MAP) 💡 The opportunities and challenges that come with addressing a global unmet need as an Australian company.   If you're heading to the 2025 Life Sciences Summit, make sure to catch Angus’ keynote on day two and reach out to connect 👉 https://lnkd.in/gwVFrE2u   #BiotechInnovation #NeedleFreeVaccines #FutureOfMedicine

Building on our recent announcement, we’re excited to welcome Dr nathalie garcon as an advisor to Vaxxas.  A globally recognised leader in #vaccine technology, Dr Garçon previously served as Vice President and Head of the Global Adjuvant Centre for Vaccine Development at GSK. Her pioneering work has led to the licensure of several adjuvanted vaccines, including Cervarix, Pandemrix, and Shingrix. With deep expertise in vaccine development, manufacturing, and regulatory strategy, Dr Garçon brings invaluable insight to #Vaxxas as we advance our HD-MAP technology towards commercialisation. "To fight, contain and treat epidemics requires proactive technology solutions adapted to meet the public health need and to allow for rapid deployment and care to a global world. Vaxxas’ HD-MAP technology has the potential to play a significant role in this equation." We’re thrilled to have Dr Garçon on board as we work to transform vaccine delivery. #Vaxxas #MedicalInnovation #Vaccines #PublicHealth #GlobalHealth

⌛️ Time is running out to save on registration for Microneedles 2025 – the premier global event shaping the future of microneedle technology.     👉 Early Bird ends tomorrow 12 March – Don’t Miss Out!  Join global experts in drug delivery, diagnostics & vaccines.  11-14 May 2025 | Brisbane, Australia     Hurry – Register now & save: https://lnkd.in/gaFjy6Wm #Vaxxas is excited to be a presenting partner of this year’s event with The University of Queensland.  #Microneedles2025 #MedicalInnovation 

Vaxxas continues to build evidence supporting the potential for needle-free vaccine patch technology to administer different vaccine types.  New pre-clinical data published in science journal Heliyon has shown the potential for Vaxxas’ proprietary high-density microarray (HD-MAP) technology to deliver DNA-based vaccines.  The research, in collaboration with The University of Queensland, assessed the use of the Vaxxas HD-MAP to deliver Technovalia’s DNA-based COVID-19 vaccine candidate to the skin.  COVID-19 continues to be a global health burden which the @Centers for Disease Control and Prevention says requires ongoing management with effective prevention and treatment strategies for reducing the impact. The reported findings build upon a recent report on effective HD-MAP delivery of mRNA-based vaccines under a program funded by the Coalition for Epidemic Preparedness Innovations (CEPI).  Beyond infectious diseases, DNA-based vaccines have shown promise as next-generation immunotherapeutic agents in cancer treatment, supporting the possible extension of HD-MAP delivery to a broader range of disease categories.  Thanks to the research teams A/Prof. David Muller, Dr Christopher McMillan , Danushka Wijesundara, PhD  and Prof. Paul Young  for uncovering these promising findings. Read more here: https://lnkd.in/gegX_P8T #medicalinnovation #Vaxxas

Following our recent announcement on expanding Vaxxas’ global expertise, we’re pleased to spotlight Dr. Emilio Emini, who joins us as a scientific advisor.  With decades of global leadership experience in vaccine research - including with the Gates Medical Research Institute, Pfizer, and Merck Group – Dr Emini brings invaluable insight to #Vaxxas as we advance our HD-MAP technology towards commercialisation. Dr Emini’s perspective on vaccine accessibility aligns with our mission of creating a healthier world through patient-focused innovation, “The development of technologies like Vaxxas’ HD-MAP can substantially enhance the global use of essential vaccines.” We’re thrilled to have Dr. Emini on board as we work towards transforming vaccine delivery worldwide. Welcome to the team, Dr. Emini! 🙌 📆 Dr Emini will also be a keynote speaker at the upcoming International Conference on Microneedles in Brisbane from 11 – 14 May. Don’t miss the opportunity to hear from this global health leader. Register now @ Microneedles 2025 | Brisbane, Australia: https://lnkd.in/gya5dixG #MedicalInnovation #Vaccines #PublicHealth #GlobalImpact

☕ What does your morning coffee and vaccine technology have in common? More than you might think! Thank you to CEPI (Coalition for Epidemic Preparedness Innovations) for including us in this recent article spotlighting #pandemic-busting innovations such as Vaxxas’ high-density microarray patch (HD-MAP) technology. At Vaxxas, we’re proud of the work we’re doing with #CEPI to increase access globally to life-saving vaccines by stabilising mRNA vaccines on our HD-MAP, reducing the need for ultra-cold chain storage and distribution. To ensure the safe and effective delivery of our vaccine-coated HD-MAP technology to the skin, we’ve taken inspiration from the precision of the humble coffee capsule to develop an applicator device that can be manufactured in large volumes, at low cost to meet high-quality standards. Find out more 👉 https://lnkd.in/eAZEAEMG  #Vaxxas #MedicalInnovation #Vaccines